These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20134488)

  • 21. Management of diverticular disease: is there room for rifaximin?
    Papi C; Koch M; Capurso L
    Chemotherapy; 2005; 51 Suppl 1():110-4. PubMed ID: 15855755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mesalamine (5-ASA) for the prevention of recurrent diverticulitis (Review).
    Carabotti M; Annibale B
    Tech Coloproctol; 2019 Jun; 23(6):597-599. PubMed ID: 31346815
    [No Abstract]   [Full Text] [Related]  

  • 23. American Gastroenterological Association Institute Technical Review on the Management of Acute Diverticulitis.
    Strate LL; Peery AF; Neumann I
    Gastroenterology; 2015 Dec; 149(7):1950-1976.e12. PubMed ID: 26453776
    [No Abstract]   [Full Text] [Related]  

  • 24. Irritable bowel syndrome and colonic diverticular disease: overlapping symptoms and overlapping therapeutic approaches.
    Alamo RZ; Quigley EMM
    Curr Opin Gastroenterol; 2019 Jan; 35(1):27-33. PubMed ID: 30407258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practice parameters for the treatment of colonic diverticular disease: Italian Society of Colon and Rectal Surgery (SICCR) guidelines.
    Binda GA; Cuomo R; Laghi A; Nascimbeni R; Serventi A; Bellini D; Gervaz P; Annibale B;
    Tech Coloproctol; 2015 Oct; 19(10):615-26. PubMed ID: 26377584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preventing diverticulitis recurrence by selecting the right therapy for a complex disease.
    Tursi A; Danese S
    Gastroenterology; 2014 Oct; 147(4):733-6. PubMed ID: 25167986
    [No Abstract]   [Full Text] [Related]  

  • 27. One year intermittent rifaximin plus fibre supplementation vs. fibre supplementation alone to prevent diverticulitis recurrence: a proof-of-concept study.
    Lanas A; Ponce J; Bignamini A; Mearin F
    Dig Liver Dis; 2013 Feb; 45(2):104-9. PubMed ID: 23092785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials.
    Raskin JB; Kamm MA; Jamal MM; Márquez J; Melzer E; Schoen RE; Szalóki T; Barrett K; Streck P
    Gastroenterology; 2014 Oct; 147(4):793-802. PubMed ID: 25038431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders].
    Gasztonyi B; Hunyady B
    Orv Hetil; 2004 Oct; 145(43):2177-81. PubMed ID: 15575494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE).
    Cuomo R; Barbara G; Annibale B
    Dig Liver Dis; 2017 Jun; 49(6):595-603. PubMed ID: 28215517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reply: To PMID 25167986.
    Raskin JB; Kamm MA; Streck P
    Gastroenterology; 2015 Apr; 148(4):856-7. PubMed ID: 25726740
    [No Abstract]   [Full Text] [Related]  

  • 32. Mesalazine for People with Diverticular Disease: A Systematic Review of Randomized Controlled Trials.
    Iannone A; Ruospo M; Wong G; Barone M; Principi M; Di Leo A; Strippoli GFM
    Can J Gastroenterol Hepatol; 2018; 2018():5437135. PubMed ID: 30320044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon.
    Latella G; Pimpo MT; Sottili S; Zippi M; Viscido A; Chiaramonte M; Frieri G
    Int J Colorectal Dis; 2003 Jan; 18(1):55-62. PubMed ID: 12458383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Chronic diverticular diseases. Rifaximin reduces symptoms and complications].
    MMW Fortschr Med; 2010 May; 152(21):98-9. PubMed ID: 20608137
    [No Abstract]   [Full Text] [Related]  

  • 35. Colonic diverticular disease.
    Simpson J; Spiller R
    Clin Evid; 2005 Dec; (14):543-50. PubMed ID: 16620420
    [No Abstract]   [Full Text] [Related]  

  • 36. American Gastroenterological Association Institute Guideline on the Management of Acute Diverticulitis.
    Stollman N; Smalley W; Hirano I;
    Gastroenterology; 2015 Dec; 149(7):1944-9. PubMed ID: 26453777
    [No Abstract]   [Full Text] [Related]  

  • 37. Review article: uncomplicated diverticular disease of the colon.
    Petruzziello L; Iacopini F; Bulajic M; Shah S; Costamagna G
    Aliment Pharmacol Ther; 2006 May; 23(10):1379-91. PubMed ID: 16669953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial.
    Stollman N; Magowan S; Shanahan F; Quigley EM;
    J Clin Gastroenterol; 2013 Aug; 47(7):621-9. PubMed ID: 23426454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Role of prebiotics and probiotics in therapeutic management of cryptogenetic inflammatory bowel disease].
    Marteau P; Seksik P
    Gastroenterol Clin Biol; 2001 Sep; 25(2 Pt 2):C94-7. PubMed ID: 11787388
    [No Abstract]   [Full Text] [Related]  

  • 40. Retrospective comparison of long-term ten-day/month rifaximin or mesalazine in prevention of relapse in acute diverticulitis.
    Festa V; Spila Alegiani S; Chiesara F; Moretti A; Bianchi M; Dezi A; Traversa G; Koch M
    Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1397-1404. PubMed ID: 28387885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.